-
公开(公告)号：US20120264684A1
公开(公告)日：2012-10-18
申请号：US13502723
申请日：2010-10-25
申请人： Yasuhiro Kajihara , Takashi Tsuji , Yuri Nambu , Kazuyuki Ishii , Kenta Yoshida , Katsunari Tezuka
发明人： Yasuhiro Kajihara , Takashi Tsuji , Yuri Nambu , Kazuyuki Ishii , Kenta Yoshida , Katsunari Tezuka
IPC分类号： C07K14/605 , A61P3/10 , A61K38/26
CPC分类号： C07K14/605 , A61K38/00
摘要： Disclosed is a glucagon-like peptide-1 (GLP-1) analogue which is obtained by ameliorating a highly antigenic GLP-1 analogue so that the GLP-1 analogue has reduced antigenicity without being lowered in the blood glucose suppressing activity. Specifically disclosed is a glycosylated form of an antigenic GLP-1 analogue, which has GLP-1 activity and is obtained by substituting at least one amino acid of an antigenic GLP-1 analogue with a glycosylated amino acid.
摘要翻译： 公开了通过改善高度抗原性GLP-1类似物而获得的胰高血糖素样肽-1（GLP-1）类似物，使得GLP-1类似物具有降低的抗原性而不降低血糖抑制活性。 具体公开的是具有GLP-1活性的抗原性GLP-1类似物的糖基化形式，其通过用糖基化氨基酸取代抗原性GLP-1类似物的至少一个氨基酸获得。
-
公开(公告)号：US08765669B2
公开(公告)日：2014-07-01
申请号：US12999654
申请日：2009-06-15
申请人： Yasuhiro Kajihara , Takashi Tsuji , Izumi Sakamoto , Yuri Nambu , Naohiro Hayashi , Kazuyuki Ishii , Kazuhiro Fukae , Katsunari Tezuka , Hiroaki Asai
发明人： Yasuhiro Kajihara , Takashi Tsuji , Izumi Sakamoto , Yuri Nambu , Naohiro Hayashi , Kazuyuki Ishii , Kazuhiro Fukae , Katsunari Tezuka , Hiroaki Asai
CPC分类号： C07K14/605 , A61K38/00
摘要： Oligosaccharide chain added GLP-1 peptides are more stable in blood and more active in controlling blood-sugar levels than GLP-1 peptides without added oligosaccharides. Oligosaccharide chain added GLP-1 peptides having GLP-1 activity include at least one or at least two amino acids each substituted with an oligosaccharide chain added amino acid in GLP-1; a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or a GLP-1 analog. Oligosaccharide chain added GLP-1 peptides with at least one amino acid substituted with an oligosaccharide chain added amino acid include an oligosaccharide chain with oligo hyaluronic acid. Oligosaccharide chain added amino acids include oligosaccharide chains attached to amino acids via linkers.
摘要翻译： 添加糖链的GLP-1肽在血液中更稳定，并且在没有添加低聚糖的情况下比GLP-1肽更有效地控制血糖水平。 具有GLP-1活性的添加糖链的GLP-1肽包括GLP-1中由糖链连接的氨基酸取代的至少一个或至少两个氨基酸; 具有GLP-1的氨基酸序列的肽，其具有缺失，取代或添加一个或几个氨基酸; 或GLP-1类似物。 具有至少一个被寡糖链添加的氨基酸取代的氨基酸的添加糖链的GLP-1肽包括具有寡聚透明质酸的寡糖链。 寡糖链添加的氨基酸包括通过接头连接到氨基酸的寡糖链。
-
公开(公告)号：US20110195897A1
公开(公告)日：2011-08-11
申请号：US12999654
申请日：2009-06-15
申请人： Yasuhiro Kajihara , Takashi Tsuji , Izumi Sakamoto , Yuri Nambu , Naohiro Hayashi , Kazuyuki Ishii , Kazuhiro Fukae , Katsunari Tezuka , Hiroaki Asai
发明人： Yasuhiro Kajihara , Takashi Tsuji , Izumi Sakamoto , Yuri Nambu , Naohiro Hayashi , Kazuyuki Ishii , Kazuhiro Fukae , Katsunari Tezuka , Hiroaki Asai
IPC分类号： A61K38/26 , C07K14/605 , A61P3/10
CPC分类号： C07K14/605 , A61K38/00
摘要： Oligosaccharide chain added GLP-1 peptides are more stable in blood and more active in controlling blood-sugar levels than GLP-1 peptides without added oligosaccharides. Oligosaccharide chain added GLP-1 peptides having GLP-1 activity include at least one or at least two amino acids each substituted with an oligosaccharide chain added amino acid in GLP-1; a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or a GLP-1 analog. Oligosaccharide chain added GLP-1 peptides with at least one amino acid substituted with an oligosaccharide chain added amino acid include an oligosaccharide chain with oligo hyaluronic acid. Oligosaccharide chain added amino acids include oligosaccharide chains attached to amino acids via linkers.
摘要翻译： 添加糖链的GLP-1肽在血液中更稳定，并且在没有添加低聚糖的情况下比GLP-1肽更有效地控制血糖水平。 具有GLP-1活性的添加糖链的GLP-1肽包括GLP-1中由糖链连接的氨基酸取代的至少一个或至少两个氨基酸; 具有GLP-1的氨基酸序列的肽，其具有缺失，取代或添加一个或几个氨基酸; 或GLP-1类似物。 具有至少一个被寡糖链添加的氨基酸取代的氨基酸的添加糖链的GLP-1肽包括具有寡聚透明质酸的寡糖链。 寡糖链添加的氨基酸包括通过接头连接到氨基酸的寡糖链。
-
公开(公告)号：US20120047586A9
公开(公告)日：2012-02-23
申请号：US12739480
申请日：2008-10-23
申请人： Takashi Tsuji , Yasuhiro Kajihara , Katsunari Tezuka , Yuri Nambu , Kazuhiro Fukae , Hiroaki Asai
发明人： Takashi Tsuji , Yasuhiro Kajihara , Katsunari Tezuka , Yuri Nambu , Kazuhiro Fukae , Hiroaki Asai
CPC分类号： C07K16/00 , A61K38/00 , C07K16/2887 , C07K2317/72 , C07K2317/732 , C07K2319/30 , C07K2319/33
摘要： Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function.
摘要翻译： 公开了具有增强的效应子功能的多肽。 具体公开的是：具有修饰的Fc区的多肽; 编码该多肽的核酸; 携带核酸的载体; 携带载体的宿主细胞或宿主生物体; 包含该多肽的药物组合物; 一种生产该多肽的方法; 用于增强抗体的效应子功能的方法; 以及能够产生具有高效应功能的抗体的细胞的制备方法。
-
公开(公告)号：US08507429B2
公开(公告)日：2013-08-13
申请号：US13152082
申请日：2011-06-02
申请人： Yasuhiro Kajihara , Takashi Tsuji , Izumi Sakamoto , Yuri Nambu , Kazuhiro Fukae , Katsunari Tezuka , Hiroaki Asai
发明人： Yasuhiro Kajihara , Takashi Tsuji , Izumi Sakamoto , Yuri Nambu , Kazuhiro Fukae , Katsunari Tezuka , Hiroaki Asai
CPC分类号： C07K14/605 , A61K38/00
摘要： The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.
摘要翻译： 本发明涉及一种与GLP-1相比血液中稳定性更高的糖链附加GLP-1肽，优选表现出比GLP-1更高的控制血糖水平的活性。 本发明涉及：（a）GLP-1;具有GLP-1活性的附加了糖链的GLP-1肽，其中至少一个氨基酸被添加了糖链的氨基酸取代。 （b）具有缺失，取代或添加一个或几个氨基酸的具有GLP-1氨基酸序列的肽; 或（c）GLP-1类似物。
-
公开(公告)号：US07985731B2
公开(公告)日：2011-07-26
申请号：US12140866
申请日：2008-06-17
申请人： Yasuhiro Kajihara , Takashi Tsuji , Izumi Sakamoto , Yuri Nambu , Kazuhiro Fukae , Katsunari Tezuka , Hiroaki Asai
发明人： Yasuhiro Kajihara , Takashi Tsuji , Izumi Sakamoto , Yuri Nambu , Kazuhiro Fukae , Katsunari Tezuka , Hiroaki Asai
CPC分类号： C07K14/605 , A61K38/00
摘要： The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.
摘要翻译： 本发明涉及一种与GLP-1相比血液中稳定性更高的糖链附加GLP-1肽，优选表现出比GLP-1更高的控制血糖水平的活性。 本发明涉及：（a）GLP-1;具有GLP-1活性的附加了糖链的GLP-1肽，其中至少一个氨基酸被添加了糖链的氨基酸取代。 （b）具有缺失，取代或添加一个或几个氨基酸的具有GLP-1氨基酸序列的肽; 或（c）GLP-1类似物。
-
公开(公告)号：US20090111739A1
公开(公告)日：2009-04-30
申请号：US12140866
申请日：2008-06-17
申请人： Yasuhiro Kajihara , Takashi Tsuji , Izumi Sakamoto , Yuri Nambu , Kazuhiro Fukae , Katsunari Tezuka , Hiroaki Asai
发明人： Yasuhiro Kajihara , Takashi Tsuji , Izumi Sakamoto , Yuri Nambu , Kazuhiro Fukae , Katsunari Tezuka , Hiroaki Asai
CPC分类号： C07K14/605 , A61K38/00
摘要： The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.
摘要翻译： 本发明涉及一种与GLP-1相比血液中稳定性更高的糖链附加GLP-1肽，优选表现出比GLP-1更高的控制血糖水平的活性。 本发明涉及：（a）GLP-1;具有GLP-1活性的附加了糖链的GLP-1肽，其中至少一个氨基酸被添加了糖链的氨基酸取代。 （b）具有缺失，取代或添加一个或几个氨基酸的具有GLP-1氨基酸序列的肽; 或（c）GLP-1类似物。
-
公开(公告)号：US20100306864A1
公开(公告)日：2010-12-02
申请号：US12739480
申请日：2008-10-23
申请人： Takashi Tsuji , Yasuhiro Kajihara , Katsunari Tezuka , Yuri Nambu , Kazuhiro Fukae , Hiroaki Asai
发明人： Takashi Tsuji , Yasuhiro Kajihara , Katsunari Tezuka , Yuri Nambu , Kazuhiro Fukae , Hiroaki Asai
CPC分类号： C07K16/00 , A61K38/00 , C07K16/2887 , C07K2317/72 , C07K2317/732 , C07K2319/30 , C07K2319/33
摘要： Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function.
摘要翻译： 公开了具有增强的效应子功能的多肽。 具体公开的是：具有修饰的Fc区的多肽; 编码该多肽的核酸; 携带核酸的载体; 携带载体的宿主细胞或宿主生物体; 包含该多肽的药物组合物; 一种生产该多肽的方法; 用于增强抗体的效应子功能的方法; 以及能够产生具有高效应功能的抗体的细胞的制备方法。
-
9.发明申请SUGAR CHAIN-ADDED AILIM EXTRACELLULAR DOMAIN AND METHOD FOR PRODUCING SAME 审中-公开糖链添加的AILIM细胞域及其生产方法公开(公告)号：US20120114595A1
公开(公告)日：2012-05-10
申请号：US13383845
申请日：2010-07-12
CPC分类号： A61K38/177 , A61K47/61 , C07K1/1077 , C07K14/70503 , C12P21/005
摘要： Disclosed is a synthetic AILIM extracellular domain which has high ligand-binding ability and a quality sufficient for a pharmaceutical product. Also disclosed is a method for synthesizing the synthetic AILIM extracellular domain. Specifically disclosed is a sugar chaim-added AILIM extracellular domain wherein a sugar chain is bound at a position corresponding to the 69-position of the amino acid sequence of human AILIM extracellular domain, said amino acid sequence being depicted in SEQ ID NO: 7, and no sugar chain is added at positions corresponding to the 3-position and the 90-position of the amino acid sequence.
摘要翻译： 公开了具有高配体结合能力和足够用于药物产品的质量的合成的AILIM细胞外结构域。 还公开了合成AILIM胞外结构域的方法。 具体公开的是加入糖链的AILIM细胞外结构域，其中糖链在对应于人AILIM细胞外结构域的氨基酸序列的69位的位置上结合，所述氨基酸序列如SEQ ID NO：7所示， 并且在对应于氨基酸序列的3-位和90位的位置处不添加糖链。
-
公开(公告)号：US20100080794A1
公开(公告)日：2010-04-01
申请号：US12296901
申请日：2007-04-12
申请人： Takashi Tsuji , Yasuhiro Kajihara , Yuri Nambu , Kazuhiro Fukae , Hiroaki Asai , Akihiro Murakami
发明人： Takashi Tsuji , Yasuhiro Kajihara , Yuri Nambu , Kazuhiro Fukae , Hiroaki Asai , Akihiro Murakami
CPC分类号： C07K14/47 , C07K16/2887 , C07K2317/41 , C07K2317/72 , C07K2317/732
摘要： Mutant polypeptides of the present invention contain an Fc region in which a cysteine residue is substituted for the second amino acid from the glycosylation site to the N terminal side in the Fc region. The Fc region is preferably a human IgG Fc region. The mutant polypeptides of the present invention may also contain an N-linked sugar chain at the glycosylation site in Fc region. Furthermore, a polypeptide domain other than the Fc region of the mutant polypeptides of the present invention may be a polypeptide molecule that recognizes a human cell surface molecule.
摘要翻译： 本发明的突变体多肽含有Fc区，其中半胱氨酸残基取代Fc区中糖基化位点至N末端侧的第二个氨基酸。 Fc区优选为人IgG Fc区。 本发明的突变体多肽还可以在Fc区的糖基化位点含有N-连接的糖链。 此外，本发明的突变多肽的Fc区以外的多肽结构域可以是识别人细胞表面分子的多肽分子。
-
-
-
-
-
-
-
-
-
搜索结果
98 条记录 (耗时 0.036 秒)
